Ser661

Site Information
GKKRLEksPsFAsEW SwissProt Entrez-Gene
Blast this site against: NCBI SwissProt PDB
Site Group ID: 484144

In vivo Characterization
Methods used to characterize site in vivo:	mass spectrometry ( 1 , 2 , 3 , 4 , 5 , 7 , 8 , 10 , 11 , 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 )
Disease tissue studied:	breast cancer ( 4 , 8 ) , breast ductal carcinoma ( 4 ) , HER2 positive breast cancer ( 1 ) , luminal A breast cancer ( 1 ) , luminal B breast cancer ( 1 ) , breast cancer, triple negative ( 1 , 4 ) , cervical cancer ( 14 ) , cervical adenocarcinoma ( 14 ) , leukemia ( 10 ) , acute myelogenous leukemia ( 10 ) , lung cancer ( 8 ) , non-small cell lung cancer ( 8 ) , ovarian cancer ( 4 ) , melanoma skin cancer ( 2 )
Relevant cell line - cell type - tissue:	293 (epithelial) ( 16 ) , breast ( 1 , 4 ) , BT-20 (breast cell) ( 8 ) , BT-549 (breast cell) ( 8 ) , Calu 6 (pulmonary) ( 8 ) , H2009 (pulmonary) ( 8 ) , H2077 (pulmonary) ( 8 ) , H2887 (pulmonary) ( 8 ) , H322M (pulmonary) ( 8 ) , HCC2279 (pulmonary) ( 8 ) , HCC366 (pulmonary) ( 8 ) , HCC78 (pulmonary) ( 8 ) , HCC827 (pulmonary) ( 8 ) , HeLa (cervical) ( 3 , 7 , 12 , 15 , 17 , 18 , 20 ) , HeLa S3 (cervical) ( 14 ) , HOP62 (pulmonary) ( 8 ) , HUES-9 ('stem, embryonic') ( 11 ) , Jurkat (T lymphocyte) ( 5 , 19 ) , K562 (erythroid) ( 7 ) , KG-1 (myeloid) ( 10 ) , LCLC-103H (pulmonary) ( 8 ) , leukocyte-blood ( 13 ) , LOU-NH91 (squamous) ( 8 ) , MDA-MB-231 (breast cell) ( 8 ) , MDA-MB-468 (breast cell) ( 8 ) , NCI-H1568 (pulmonary) ( 8 ) , NCI-H1648 (pulmonary) ( 8 ) , NCI-H2172 (pulmonary) ( 8 ) , NCI-H322 (pulmonary) ( 8 ) , NCI-H460 (pulmonary) ( 8 ) , NCI-H520 (squamous) ( 8 ) , NCI-H647 (pulmonary) ( 8 ) , ovary ( 4 ) , PC9 (pulmonary) ( 8 ) , WM239A (melanocyte) ( 2 )

Upstream Regulation
Treatments:	EGF ( 15 ) , nocodazole ( 14 ) , U0126 ( 15 )

References
1	Mertins P, et al. (2016) Proteogenomics connects somatic mutations to signalling in breast cancer. Nature 534, 55-62 27251275 Curated Info
2	Stuart SA, et al. (2015) A Phosphoproteomic Comparison of B-RAFV600E and MKK1/2 Inhibitors in Melanoma Cells. Mol Cell Proteomics 14, 1599-615 25850435 Curated Info
3	Sharma K, et al. (2014) Ultradeep human phosphoproteome reveals a distinct regulatory nature of Tyr and Ser/Thr-based signaling. Cell Rep 8, 1583-94 25159151 Curated Info
4	Mertins P, et al. (2014) Ischemia in tumors induces early and sustained phosphorylation changes in stress kinase pathways but does not affect global protein levels. Mol Cell Proteomics 13, 1690-704 24719451 Curated Info
5	Mertins P, et al. (2013) Integrated proteomic analysis of post-translational modifications by serial enrichment. Nat Methods 10, 634-7 23749302 Curated Info
6	Shiromizu T, et al. (2013) Identification of missing proteins in the neXtProt database and unregistered phosphopeptides in the PhosphoSitePlus database as part of the Chromosome-centric Human Proteome Project. J Proteome Res 12, 2414-21 23312004 Curated Info
7	Zhou H, et al. (2013) Toward a comprehensive characterization of a human cancer cell phosphoproteome. J Proteome Res 12, 260-71 23186163 Curated Info
8	Klammer M, et al. (2012) Phosphosignature predicts dasatinib response in non-small cell lung cancer. Mol Cell Proteomics 11, 651-68 22617229 Curated Info
9	Beli P, et al. (2012) Proteomic Investigations Reveal a Role for RNA Processing Factor THRAP3 in the DNA Damage Response. Mol Cell 46, 212-25 22424773 Curated Info
10	Weber C, Schreiber TB, Daub H (2012) Dual phosphoproteomics and chemical proteomics analysis of erlotinib and gefitinib interference in acute myeloid leukemia cells. J Proteomics 75, 1343-56 22115753 Curated Info
11	Rigbolt KT, et al. (2011) System-wide temporal characterization of the proteome and phosphoproteome of human embryonic stem cell differentiation. Sci Signal 4, rs3 21406692 Curated Info
12	Kettenbach AN, et al. (2011) Quantitative phosphoproteomics identifies substrates and functional modules of aurora and polo-like kinase activities in mitotic cells. Sci Signal 4, rs5 21712546 Curated Info
13	Raijmakers R, et al. (2010) Exploring the human leukocyte phosphoproteome using a microfluidic reversed-phase-TiO2-reversed-phase high-performance liquid chromatography phosphochip coupled to a quadrupole time-of-flight mass spectrometer. Anal Chem 82, 824-32 20058876 Curated Info
14	Olsen JV, et al. (2010) Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis. Sci Signal 3, ra3 20068231 Curated Info
15	Pan C, Olsen JV, Daub H, Mann M (2009) Global effects of kinase inhibitors on signaling networks revealed by quantitative phosphoproteomics. Mol Cell Proteomics 8, 2796-808 19651622 Curated Info
16	Gauci S, et al. (2009) Lys-N and trypsin cover complementary parts of the phosphoproteome in a refined SCX-based approach. Anal Chem 81, 4493-501 19413330 Curated Info
17	Chen Y, et al. (2009) Combined integrin phosphoproteomic analyses and small interfering RNA--based functional screening identify key regulators for cancer cell adhesion and migration. Cancer Res 69, 3713-20 19351860 Curated Info
18	Chen RQ, et al. (2009) CDC25B mediates rapamycin-induced oncogenic responses in cancer cells. Cancer Res 69, 2663-8 19276368 Curated Info
19	Mayya V, et al. (2009) Quantitative phosphoproteomic analysis of T cell receptor signaling reveals system-wide modulation of protein-protein interactions. Sci Signal 2, ra46 19690332 Curated Info
20	Dephoure N, et al. (2008) A quantitative atlas of mitotic phosphorylation. Proc Natl Acad Sci U S A 105, 10762-7 18669648 Curated Info